On July 9th 2013, Calimmune announced they had treated the first patient in a clinical trial involving the use of an innovative gene-based stem cell therapy to help protect individuals infected with HIV from the effects of the AIDS virus. Calimmune CEO Louis Breton spoke to the governing board of California's Stem Cell Agency (CIRM) about the trial. He described the current statistics of HIV infection in the US and globally and explained why their experimental treatment is needed. CIRM is helping fund the trial through a CIRM Disease Team grant.
For more information, see the CIRM HIV/AIDS fact sheet